- Strategic Relationship: Agreement expands access to ECMO
solutions for hospitals, health systems and patients in the U.S.
nationwide.
- Wide Reach: 4,350+ Premier member hospitals and health systems
in the U.S. can leverage pre-negotiated terms and pricing on
the Novalung System for ECMO.
- Commitment to Quality Care: Reinforces company's commitment to
supporting healthcare providers in their efforts to deliver
high-quality critical care treatments and solutions.
BAD HOMBURG, Germany, Nov. 19,
2024 /PRNewswire/ -- Fresenius Medical
Care (FME), the world's leading provider of products and
services for individuals with renal diseases, today announced its
heart and lung group has been awarded a national group purchasing
agreement for Mechanical Circulatory Support with Premier, Inc in
the U.S. Since acquiring Xenios in 2016, Fresenius Medical Care has
been dedicated to advancing heart and lung therapy. The agreement
underscores FME's commitment to critical care solutions and allows
Premier member hospitals and health systems, at their discretion,
to take advantage of special pricing and terms pre-negotiated by
Premier for the Novalung System.
"We are excited to be awarded this agreement by Premier, which
will help broaden the reach of our Novalung ECMO System," said Olaf
Schermeier, PhD, Chief Executive Officer, Critical Care &
Ventures at Fresenius Medical Care. "This agreement highlights our
dedication to delivering safe, simple, and portable solutions and
enhancing patient outcomes in critical care units in the United States. Through our agreement with
Premier, we aim to better serve healthcare providers with efficient
heart and lung support therapy, helping to improve survival rates
and recovery for patients with severe cardiac or pulmonary failure.
The rapidly shifting market dynamics may increase risks to
hospitals, and this agreement provides broader access with the
Novalung System for ECMO."
The Novalung System for extracorporeal membrane oxygenation
(ECMO), was the first system FDA-cleared for long-term (>6hr)
ECMO, providing a critical offering to patients and hospitals. The
system pumps and oxygenates the blood of patients with acute
respiratory failure or acute cardiopulmonary failure. Novalung
offers a portable therapy solution designed to improve clinical
outcomes and accommodate various clinical care settings such as
intensive care units, operating rooms, cardiac catheterization labs
and emergency departments.
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,350 U.S. hospitals and 300,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, and consulting
and other services, Premier enables better care and outcomes at a
lower cost.
For more information about Fresenius Medical Care and the
Novalung® System for ECMO, please visit
https://fmcna.com/products/novalung-ecmo-therapy/novalung/.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
4.1 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,732 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approx. 308,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care
does not undertake any responsibility to update the forward-looking
statements in this release.
Media contact
Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-awarded-mechanical-circulatory-support-agreement-with-premier-inc-for-the-novalung-ecmo-system-302309872.html
SOURCE Fresenius Medical Care Holdings, Inc.